DK0653211T3 - Blodkoagulationsnormalisator indeholdende TCF-II som aktiv bestanddel - Google Patents

Blodkoagulationsnormalisator indeholdende TCF-II som aktiv bestanddel

Info

Publication number
DK0653211T3
DK0653211T3 DK93916161T DK93916161T DK0653211T3 DK 0653211 T3 DK0653211 T3 DK 0653211T3 DK 93916161 T DK93916161 T DK 93916161T DK 93916161 T DK93916161 T DK 93916161T DK 0653211 T3 DK0653211 T3 DK 0653211T3
Authority
DK
Denmark
Prior art keywords
blood coagulation
normalizer
active ingredient
containing tcf
tcf
Prior art date
Application number
DK93916161T
Other languages
Danish (da)
English (en)
Inventor
Hiroaki Masunaga
Nobuaki Fujise
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of DK0653211T3 publication Critical patent/DK0653211T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK93916161T 1992-07-16 1993-07-14 Blodkoagulationsnormalisator indeholdende TCF-II som aktiv bestanddel DK0653211T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21222892 1992-07-16
JP11780993 1993-04-21
PCT/JP1993/000974 WO1994002165A1 (en) 1992-07-16 1993-07-14 Blood coagulation normalizer containing tcf-ii as active ingredient

Publications (1)

Publication Number Publication Date
DK0653211T3 true DK0653211T3 (da) 2002-05-06

Family

ID=26455863

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93916161T DK0653211T3 (da) 1992-07-16 1993-07-14 Blodkoagulationsnormalisator indeholdende TCF-II som aktiv bestanddel

Country Status (11)

Country Link
US (1) US5714461A (es)
EP (1) EP0653211B1 (es)
JP (1) JP3634359B2 (es)
KR (1) KR100260964B1 (es)
AT (1) ATE206929T1 (es)
AU (1) AU674871B2 (es)
CA (1) CA2140010C (es)
DE (1) DE69330960T2 (es)
DK (1) DK0653211T3 (es)
ES (1) ES2165855T3 (es)
WO (1) WO1994002165A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275718A3 (en) * 1994-12-27 2003-03-19 Daiichi Pharmaceutical Co., Ltd. TCF mutant
WO1997012628A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Methods and compositions for treating vascular stenosis
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ATE344050T1 (de) 1997-03-14 2006-11-15 Daiichi Seiyaku Co Verwendung von tcf-ii zur behandlung von durch krebs verursachtem gewichtsverlust, anaemie und tnf-erhöhung
JPH1129493A (ja) * 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
JPH11269091A (ja) * 1998-03-19 1999-10-05 Snow Brand Milk Prod Co Ltd 敗血症予防及び／又は治療剤
US7741452B2 (en) 2003-12-16 2010-06-22 Toshikazu Nakamura Glycosylation-deficient hepatocyte growth factor
US7262637B2 (en) * 2005-03-22 2007-08-28 Micron Technology, Inc. Output buffer and method having a supply voltage insensitive slew rate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076701A (en) * 1975-07-29 1978-02-28 Immunology Research Foundation, Inc. Tumor complement fraction recovery method and product
US4490549A (en) * 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
JPH0296598A (ja) * 1988-10-03 1990-04-09 Sapporo Breweries Ltd リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
ES2132087T3 (es) * 1990-07-13 1999-08-16 Snow Brand Milk Products Co Ltd Plasmidios que contienen adn que codifica la secuencia de aminoacidos de tcf-ii, celulas transformadas y produccion de la sustancia fisiologicamente activa usando las mismas.
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
CA2100720C (en) * 1992-07-16 2003-03-11 Hiroaki Masunaga Medicinal composition comprising tcf-ii
WO1994014845A1 (en) * 1992-12-28 1994-07-07 Snow Brand Milk Products Co., Ltd. Modified tcf
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤

Also Published As

Publication number Publication date
JP3634359B2 (ja) 2005-03-30
CA2140010A1 (en) 1994-02-03
KR950702433A (ko) 1995-07-29
EP0653211A4 (en) 1996-06-26
EP0653211B1 (en) 2001-10-17
AU4583393A (en) 1994-02-14
KR100260964B1 (ko) 2000-07-01
DE69330960D1 (de) 2001-11-22
US5714461A (en) 1998-02-03
DE69330960T2 (de) 2002-04-11
EP0653211A1 (en) 1995-05-17
CA2140010C (en) 2008-04-01
WO1994002165A1 (en) 1994-02-03
ES2165855T3 (es) 2002-04-01
ATE206929T1 (de) 2001-11-15
AU674871B2 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
ES2111579T3 (es) Preparaciones de factor viii estabilizadas.
ATE231885T1 (de) Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura
DE3851711D1 (de) Verwendung von Morphinantagonisten zur Herstellung von Medikamenten mit immunmodulatorischer und antiviraler Wirkung, insbesondere bestimmt zur Behandlung von erworbenen Immunmangelzuständen.
DE3683333D1 (de) Mittel zur behandlung von akne vulgaris und deren herstellung.
ATE69548T1 (de) Vitamin e-haltiges mittel zur verbesserung der eigenschaften des blutes.
DE3873327D1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
DK0653211T3 (da) Blodkoagulationsnormalisator indeholdende TCF-II som aktiv bestanddel
DE3865368D1 (de) Thiophensulfonamide zur behandlung von glaukom.
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DE69636814D1 (de) Verwendung des menschlichen choriongonadotropins in der behandlung von kaposi's-sarcoma
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ES2181722T3 (es) Marcfortinas sustituidas en la posicion 14 y derivados utiles como agentes antiparasitarios.
NO890261L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
RU95113977A (ru) Средство для лечения ран
HUT54300A (en) Process for producing medicaments suitable for antiviral treatment
RU95120823A (ru) Способ лечения гипертрофического гингивита
ATE88636T1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augenhypertension und glaukom.